-0.0107 (-2.488%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Neutral
Earnings
Strong
Earnings
Very Strong
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
GT Biopharma Inc
Telephone
1.415.919.4040
Address
10th floor, 505 Montgomery Street, San Francisco, CA 94111
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.26 - 3.85
Trade Value (12mth)
US$226,692.00
1 week
9.16%
1 month
15.37%
YTD
-47.37%
1 year
-83.83%
All time high
34425000.00
EPS 3 yr Growth
-68.20%
EBITDA Margin
0.00%
Operating Cashflow
-$13m
Free Cash Flow Return
-627.40%
ROIC
NaN%
Interest Coverage
-97.80
Quick Ratio
3.20
Shares Outstanding (Fully Diluted)
30m
HALO Sector
Healthcare
Next Company Report Date
31-Mar-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 15 May 26 | |
| 15 May 26 | |
| 07 May 26 | |
| 07 May 26 | |
| 07 April 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | -5.64 | -6.94 | -6.25 | | | | ||
EPS (Fully Diluted) | $ | | | | | -5.64 | -6.94 | -6.25 | | | | ||
Growth | % | | | | | 71.3 | -23.1 | 9.9 | | | | ||
PE | X | | | | | N/A | N/A | N/A | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
